Press Releases

Press Release: OracleBio integrates Indica Labs HALO AI to enhance Digital Pathology Software Capabilities

July 9, 2020 | by Hannah Thomson
OracleBio continues to enhance its digital pathology software capabilities by integrating Indica Labs HALO AI into its image analysis workflow. This latest step in OracleBio’s development will enable the quantitative digital pathology services provider to meet increasing demand from Pharmaceutical clients globally.

The deep learning add-on, produced by Indica Labs, comes with six distinct neural networks for classification and segmentation of tissue and nuclei, as well as a python plugin for integration of custom neural networks. The AI module fully integrates with OracleBio’s existing HALO® platform and HALO Link system, providing clients with real-time instant access to study images.

The integration of HALO AI will help OracleBio to:

• Deliver data faster: Deep learning has been shown to expedite digital pathology workflows, for example by reducing the amount of time required for manual annotations. The HALO AI module will be run on OracleBio’s AWS Cloud Server, allowing for multiple users analysing simultaneously on high powered GPUs in the cloud, which will further improve OracleBio’s turnaround time.

• Conduct more complex analysis: The HALO AI module will help OracleBio to address more challenging image analysis studies for example, by automated detection of kidney glomeruli and phenotyping of nuclei in H&E-stained tissues.

• Improve accuracy and reproducibility: Deep learning algorithms continually improve and get more precise with every additional training iteration.

Steven Hashagen, Chief Executive Officer at Indica Labs, commented:
‘HALO AI has been a gamechanger for high-throughput analysis customers like OracleBio who need solutions that improve both working efficiency and accuracy. As one of our most productive and long-standing HALO customers, we are pleased to see OracleBio expanding their technical capabilities once again with the addition of HALO AI.’

Lorcan Sherry, Chief Scientific Officer at OracleBio, commented:
‘OracleBio strives to be at the forefront of Digital Pathology and is committed to providing high quality services using the most advanced and sophisticated software. This recent expansion of our services to include Indica’s AI module will allow us to further improve our service offering and we are very excited by the benefits this will bring to our clients.’

OracleBio’s AI-powered digital pathology services are available now. To find out more or arrange an initial consultation, please contact OracleBio.

About Indica Labs
Indica Labs is the world’s leading provider of computational pathology software and services. Our flagship HALO® image analysis platform enables fast, quantitative evaluation of tissues using a broad range of artificial intelligence (AI) and computer vision algorithms. HALO Link and HALO AP™ facilitate remote image analysis, collaboration and management. Through a combination of precision, scalability, and usability our software solutions enable pharmaceutical companies, diagnostic labs, research organizations, and Indica’s own contract pharma services team to advance tissue-based research, clinical trials, and diagnostics. For more information, please visit https://stg-indicalabs-staging.kinsta.cloud or contact info@indicalab.com.

About OracleBio
OracleBio is a leading provider of quantitative digital pathology services to support pre-clinical and clinical Pharmaceutical R&D. Using industry leading image analysis software platforms, the company delivers accurate and detailed quantification of single and multiplex IHC, IF and ISH marker staining allowing for improved decision making within R&D.

Press Release: OracleBio integrates Indica Labs HALO AI to enhance Digital Pathology Software Capabilities Read More »

Press Release: Indica Labs, Octo and Axle work with NIH to launch a global COVID-19 digital pathology repository

Albuquerque, NM and Reston, VA– May 21, 2020 – Indica Labs, a leading provider of computational pathology software, and Octo, a premiere information technology systems provider to the U.S. Federal Government, are pleased to announce the online COVID Digital Pathology Repository (COVID-DPR), a virtual collection of high resolution microscopic COVID-related human tissue images hosted at the National Institutes of Health.

Press Release: Indica Labs, Octo and Axle work with NIH to launch a global COVID-19 digital pathology repository Read More »

Press Release: Indica Labs completes nationwide deployment of HALO AP™ at NeoGenomics Laboratories, Inc.

Albuquerque, NM (April 3, 2020) – Indica Labs, the leading provider of computational pathology software, is pleased to announce the formal release of its HALO AP™ Anatomic Pathology platform at NeoGenomics Laboratories, Inc.

HALO AP™ was developed by Indica Labs to address the needs of Anatomic Pathology labs. Offering a full range of tissue-based assays and workflows, the platform can be fully integrated within existing LIS solutions or can operate as a standalone case management system. HALO AP adds support for clinical trials, tumor boards, secondary consults, AI-assisted workflows, and quantitative analysis of custom laboratory developed tests (LDTs), from basic immunohistochemistry (IHC) through to novel, multiplexed immune-oncology assays.

Press Release: Indica Labs completes nationwide deployment of HALO AP™ at NeoGenomics Laboratories, Inc. Read More »

Press Release: NeoGenomics Integrates HALO® From Indica Labs

Ft. Myers, Florida – March 31, 2020 – NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused testing services, today announced that it has integrated Indica Labs enterprise-level HALO AP™ image analysis platform for Image Analysis, Immunohistochemistry (IHC) and Multiplexing across its Clinical Services and Pharma Services businesses. The platform’s robust workflow modules streamlines analysis algorithms and provides rapid, quantitative results for a multitude of tissue types.

Press Release: NeoGenomics Integrates HALO® From Indica Labs Read More »

Press Release: IONpath and Indica Labs establish a co-marketing agreement to promote spatially resolved analysis of tissues imaged with the Multiplexed Ion Beam Imaging (MIBI) System

USA 04/26/2019 – Indica Labs and IONpath announced today that a co-marketing agreement has been established to jointly promote their respective technologies for tissue-based, multiplexed

Press Release: IONpath and Indica Labs establish a co-marketing agreement to promote spatially resolved analysis of tissues imaged with the Multiplexed Ion Beam Imaging (MIBI) System Read More »

Press Release: Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ: FLDM) and Indica Labs, Inc., today announced a co-marketing relationship for scalable and

Press Release: Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations Read More »

Scroll to Top